BioSpace News Archive

Marken, the clinical supply chain leader, announced it will double the space of its GMP facility in Frankfurt to further expand its frozen room storage capabilities in anticipation of the COVID-19 vaccine and storage needs.

The EndBrainCancer Initiative announced that GT Medical Technologies, manufacturers of GammaTile Therapy for Brain Cancer Patients, has joined EBCI’s roster of corporate partners.

Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, announced the appointment of Susan Shiff, Ph.D., M.B.A., to its Board of Directors.

Vericel Corporation announced the submission of a Biologics License Application to the U.S. Food and Drug Administration seeking the approval of NexoBrid® for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

BeyondSpring Inc. announced that the Company presented clinical data on BeyondSpring’s first-in-class, late-stage asset, Plinabulin, showing potent CD34+ progenitor cell mobilization from bone marrow, which has broad applications for stem cell-based therapies, gene therapy and regenerative medicine.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, announced that it has executed a lease agreement to establish a cGMP manufacturing facility in Houston, TX, in an area near the George Bush Intercontinental Airport.

CoreLink, LLC , a leading designer and manufacturer of spinal implant systems, today announced the commercial launch and 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the F3D-C2 Stand-alone Cervical System . This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200630005144/en/ The F3D-C2 Stand-alone Cervical Spine System features an additiv

Inovio (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to protect and treat people from infectious diseases and cancer, today announced positive interim clinical data of INO-4800, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the first two Phase 1 clinical trial cohorts.

Clinical trial for patients with NASH cirrhosis who have the highest need for effective therapy Belapectin has previously shown ability to prevent the development of esophageal varices in this patient population Compelling NASH-RX trial result could potentially lead to accelerated FDA approval and/or partnership opportunities and fulfill an acute unmet medical need NORCROSS, Ga., June 30, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics, the leading developer of therapeutics that targe

BioInvent International AB (“BioInvent”) (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has submitted a clinical trial application (CTA) to begin a Phase I/IIa, first-in-human study of BI-1808, a monoclonal a